

Development of **** inhibitor for immuno-metabolic modulator

1ST Biotherapeutics, Inc.



ONCOLOGY	Lead
Product Type	Small molecule compound
Indication	Cancer
Target	Undisclosed
MoA(Mechanism of Action)	Immuno-metabolic modulator
Competitiveness	<ul style="list-style-type: none"> • Next generation immuno-oncology drug targeting immune metabolism regulators with a different mechanism from existing immune checkpoint inhibitors (PD-1, PD-L1) • Expected to be applied to various immune cells as well as T cells • First in the class in the field
Development Stage	Lead
Route of Administration	Oral